Seed Therapeutics is a pioneering biotech company focused on developing novel therapies that degrade disease-causing proteins, particularly those that have been difficult to target with traditional small molecule drugs. The company operates in the biopharmaceutical market, primarily serving patients with cancer and other serious diseases. Seed Therapeutics collaborates with leading research institutions and pharmaceutical companies, such as Lilly, to advance its drug candidates towards clinical and commercial success. The business model involves research and development of proprietary drug candidates, followed by licensing agreements and partnerships to bring these therapies to market. Revenue is generated through milestone payments, royalties, and licensing fees from these collaborations.

Keywords: protein degradation, novel therapies, cancer treatment, biopharmaceutical, drug development, research collaboration, licensing agreements, proprietary drugs, molecular glue, KRAS oncogene.